The US Patent and Trademark Office (USPTO) has granted a notice of allowance (NOA) to Hygieia's claims related to Diabetes Insulin Guidance system (DIGS) technology.
The patent covers a system which automatically optimizes a patient's insulin dosage as needed to achieve a better glycemic balance of lowered hemoglobin A1C, as well as reduced hypoglycemia frequency.
Hygieia chief executive officer Eran Bashan said, "This patent allowance greatly strengthens Hygieia's commercial position and boosts our roll out efforts in the United Kingdom, where our d-Nav Diabetes Insulin Guidance System product is currently available."
The CE-marked, handheld d-Nav device, which incorporates DIGS technology, is designed to improve diabetes care delivery.
